Rebecca Houser is the Head of Operations and Product at Protege. She has built products in startups ranging from pre-seed to post-acquisition and IPO, and across industries, including Ad Tech, Prop Tech, Health Tech, and Compliance Tech. A unifying theme of her work is finding the right combination of software and human processes to create the best solutions for customers. Rebecca earned her MBA from Stanford University and completed her undergraduate studies at Harvard University.

Beth Ginzinger is currently the Chief Transformation Officer for Blue Cross Blue Shield of Arizona (BCBSAZ) and President, Prosano Health Solutions with a focus on healthcare transformation and strategy. Beth's journey from a nurse to a top executive at BCBSAZ encapsulates her deep understanding of healthcare from the ground up. Her direct involvement in clinical care, combined with her strategic roles, underscores a career built on improving healthcare delivery.  Highlights of her experience include:

• Founder of Radiant, an international staffing solution for care management, which has since become a part of Accenture, showcasing the ability to scale solutions globally.
• Lead architect behind Anthem’s provider joint ventures, including Vivity, an integrated product offering that united 7 competitor health systems (including UCLA and Cedars Sinai) in Southern California, highlighting the ability to foster collaboration.
• Creator of Blue Cross Blue Shield of Arizona’s initial 5-year foundational strategic plan ($500M investment) which positioned the organization for two strategic acquisitions (Medicare Advantage and Medicaid plans) and ultimately drove the doubling of corporate revenue from $2.2B to $4.7B and increased market share from #2 to #1 in the state.  
• Founder of Prosano Health Solutions, Blue Cross Blue Shield of Arizona’s entity to evolve into a health solution company, and brought to market their flagship offering, BlueSignature Prosano, an Advanced Primary Care model that has integrated seamlessly with BCBSAZ, demonstrating innovative approaches to both delivery and service through a payer-provider infrastructure.
• Led volunteer deployment for Arizona’s first 24/7 vaccine clinic, exemplifying commitment to public health and innovation in healthcare accessibility. During this 3-month commitment, Beth created the structure for 147k volunteer hours over 15k shifts resulting in 490k shots of hope.

Beth has extensive Board of Director experience through service on both non-profit and private company boards, founding multiple organizations and creating their governance structure, and earning directorship certification through the National Association of Corporate Directors.  

Beth earned a Bachelor of Science in Nursing from Vanderbilt University and her Master’s in Business (Beta Gamma Sigma – top 5% nationally) from Eastern Michigan University while working full time. She has lived abroad (Switzerland) and established organizations (Radiant) in the Philippines and India.

Vera Mucaj is the prior Chief Scientific Officer at Datavant, where she led a team developing key use cases for connected health data and integrating clinical trial data with real-world evidence. She is currently a Venture Partner at Flex Capital. Vera holds a BA in Biochemistry from Harvard College and a PhD in Cell and Molecular Biology from the University of Pennsylvania Perelman School of Medicine.

 Robert M. Wachter, MD is Professor and Chair of the Department of Medicine at the University of California, San Francisco (UCSF). Author of 300 articles and 6 books, he coined the term “hospitalist” in 1996 and is often considered the “father” of the hospitalist field, the fastest-growing medical specialty in U.S. history. He is past president of the Society of Hospital Medicine, past chair of the American Board of Internal Medicine, a Master of the American College of Physicians, and an elected member of the National Academy of Medicine. In 2004, he received the John M. Eisenberg Award, the nation’s top honor in patient safety. Modern Healthcare magazine has ranked him as one of the 50 most influential physician-executives in the U.S. more than a dozen times; he was #1 on the list in 2015. His 2015 book, The Digital Doctor: Hope, Hype and Harm at the Dawn of Medicine’s Computer Age, was a New York Times science bestseller. His new book, A Giant Leap: How AI is Transforming Healthcare – and What That Means for Our Future, will be published in late 2025 by Portfolio, a Penguin-Random House imprint.

Munjal Shah is the co-founder and CEO of Hippocratic AI, a startup building the first safety-focused large language model (LLM) for healthcare. The company is on a mission to dramatically improve healthcare access, equity and outcomes through the use of generative AI. Munjal is a serial entrepreneur, startup adviser, and investor. He was co-founder and CEO of an AI company that was acquired by Google and a marketplace management, research and analytics company eventually sold to Alibaba. He graduated from Stanford with a Masters in Computer Science, focused on AI. Prior to Hippocratic AI, Munjal spent 10 years as co-founder and CEO of a healthcare startup leveraging AI to analyze health records to help seniors select the best Medicare Advantage plan.

Chris Mansi, MD is CEO and Co-Founder of Viz.ai, the leader in AI-powered disease detection and care coordination.  Viz.ai’s mission is to improve access to life saving treatments for more than 230 million people that it covers.  Today, the Viz.ai One Platform has 30 care pathways, is adopted in more than 1,700 hospitals, and collaborates with 10 of the leading, global pharmaceutical and medical device companies.  

Dr. Mansi co-founded Viz.ai out of Stanford in 2016 with a mission of using artificial intelligence to increase access to life-saving treatments.  Under his leadership, Viz.ai has achieved major AI industry milestones, including two de novo approvals by the FDA for AI computer aided triage in 2018 and cardiovascular machine learning-based notification software in 2023.  Viz.ai was also the first AI company to be granted CMS reimbursement via the New Technology Add-on Payment (NTAP) for AI in 2020.   In 2024, Viz.ai was named one of the 50 world’s most innovative companies by Fast Company Magazine, and Chris was recognized as in Time Magazine’s 100 Most Influential People in AI in 2024.

‍

Nicholas Joseph is the Head of Pretraining at Anthropic, where he has worked since its founding training large language models that power Claude. Before that, he worked on AI safety at OpenAI and computer vision and robotics at Vicarious.

Josh Harder represents California’s 9th District, centered in the diverse city of Stockton and powered by a vibrant agricultural economy dubbed the “fruit and nut basket of the world.” Josh ran for office in 2018 to stand up to politicians threatening to take his brother’s health care away. Now in his 4th term in Congress, Josh is a champion for lowering everyday costs, expanding health care access, and investing in 21st century solutions for California’s water and fire crises. As a member of the powerful House Appropriations Committee, Josh helps oversee $1.7 trillion in federal funding, and he serves on the Labor, Health & Human Services and Interior Subcommittees. Josh’s office has won national awards for bipartisanship, accessibility, and effectiveness, and he currently serves as Vice Chair of the New Democrats, the largest ideological caucus in Congress.

Josh started his career in the private sector where he focused on helping small businesses grow. After receiving a public policy and business degree from Harvard, he taught business at a local community college before entering public service. Josh is raising his two young daughters, Lillian (3) and Karina (1) with his wife Pam in Tracy, California.

‍

Shannon West is the Chief Strategy Officer for Datavant. In this position, Shannon leads digital interoperability efforts to further Datavant’s growth with innovative new technologies, solutions, and business models. She is focused on accelerating the company’s pace of innovation in making the Datavant vision possible, to power every health decision with the right data at the right time in the right format.

Prior to her time at Datavant, Shannon was the first Chief Technology Officer at the Center for Medicare and Medicaid Innovation (CMMI). She also served as part of the United States Digital Service, a start-up within the White House dedicated to bringing technical talent into government to improve the delivery of government services. During this time, she served as both the Director of Digital Service and HHS and CMS and as a Senior Advisor for Technology to the CMS Administrator. As Senior Advisor, she developed and executed on the Administration’s agenda for technology, including efforts that intertwined policy and internal technology to promote improved data sharing using modern standards and technology.

In addition to working as an advisor on various health technology initiatives for the White House and numerous federal agencies, she also worked with early-stage technology start-ups, helping develop products and market strategies for healthcare and government sectors.

‍

Bobby Samuels is the Co-Founder & CEO of Protege, a company dedicated to unlocking proprietary datasets for AI training by enabling secure, privacy-preserving data access and exchange. Prior to founding Protege, Bobby held multiple leadership roles at Datavant. As General Manager of Privacy Hub, he led efforts to expand Datavant’s privacy-preserving technology solutions, building on its position as the leading platform for healthcare data interoperability. Before Datavant, Bobby worked in partnerships and product at LiveRamp.

‍

Chris Taylor is the Co-Founder & CEO of Fractional AI, leading applied gen AI projects from automation to product launches. Previously, he was CRO at Wove (acquired by Samba TV) and a founding sales leader at LiveRamp. He holds a BS from Wharton.

‍

At Vertex Pharmaceuticals, I lead the corporate data science division that integrates and scales advanced analytics and AI (e.g. NLP, machine learning, generative AI/LLMs) across our disease areas and business including clinical, commercial, manufacturing and HR. Collaborating directly with executive management, our privacy office and IT, we've developed enterprise capabilities and a model for using AI to drive impact. My role extends to engaging with the Board of Directors annually, delivering the vision and tangible impacts of data science and AI. I assembled an elite technical team from the ground up with the goal of leveraging data in transformative ways to deliver novel insights and enable operational excellence through change management at all levels of our business.

Prior to joining Vertex in 2017, I held roles at Merck, Genentech, the White House, and the Centers for Medicare and Medicaid Services. In these roles I created the first formal data science team at Merck and while at the White House paved the wave for the first Chief Data Officers across the U.S. Government. I earned my PhD in health services research and a master's in epidemiology, with a focus on using large scale data to better understand healthcare. I have been an advisor to data/tech initiatives for the World Bank, USAID, Harvard, Cornell, Ashoka Foundation, Knight News Foundation, Boston Children's Hospital and others. I live in the Boston area with my wife, Vicki Fung, who is faculty of medicine and health policy at Harvard Medical School/Massachusetts General Hospital.

‍

Sooah is a Partner co-leading SignalFire’s Health & PharmaTech AI investment practice. SignalFire is a $2B+ AI-native VC built like a technology company to enable founder success from Seed to Scale. The fund leverages a unique tech-enabled approach to accelerate founders’ journeys with its in-house Beacon AI platform, a portfolio success team of company building experts, and Health & PharmaTech-specific advisors such as Eric Larsen to accelerate founders’ journeys. Prior to SignalFire, she was a product leader at CVS Health, where she launched nationwide prescription delivery and virtual care products, and Devoted Health, currently valued at $12B+. She invests in B2B AI applications and infrastructure for providers, payors, and pharma companies. She began her career at Michael Porter’s strategy firm where she advised healthcare & biopharma executives. Sooah has a joint-degree MBA | MPP from Harvard Business School and Harvard Kennedy School, where she worked with startup founders at the HBS Rock Center for Entrepreneurship. As a product builder, GTM strategist, and policy nerd turned investor, she partners with founders at the earliest stages of their discovery, building, and scaling journeys. She’s excited to reimagine how we develop, deliver, & pay for healthcare today and usher in a new era of AI-enabled health and longevity for all.

‍

Ari Brettman is a Senior Managing Director in the Blackstone Life Sciences group, having joined Blackstone as part of its acquisition of Clarus in December of 2018. Dr. Brettman joined Clarus in September 2014.

Dr. Brettman is focused on investments across the firm's portfolio, including company creation, spinouts, royalty monetizations, R&D risk-sharing collaborations, and structured credit with biopharmaceutical and med tech companies. Dr. Brettman has played leading roles in Blackstone Life Science’s investments in Anthos Therapeutics, where he is a founding member of the Board of Directors and initially served as Acting Chief Medical Officer, Alnylam Pharmaceuticals, AvenCell, where he is a founding member of the Board of Directors, and Pfizer. At Clarus, he played leading roles and served on the Board of Directors in portfolio companies Praxis Precision Medicines and Essa Pharmaceuticals.

Prior to Clarus, Dr. Brettman completed a residency in internal medicine and a fellowship in cardiology at Massachusetts General Hospital. Dr. Brettman was also an NIH-sponsored post-doctoral fellow at the MGH Center for Systems Biology, where he studied the autophagy of lipid droplets and used electronic medical record-based big data analytics at Partners Healthcare to conduct clinical research and improve disease management.

Dr. Brettman received his M.D. from Duke University and his A.B. in History and Science from Harvard College. While a medical student, he was a Sarnoff Cardiovascular Research Foundation Fellow at Stanford University, where he studied angiogenesis.

‍

Elyse Jones Benedicto is the Chief Operating Officer and General Counsel of Shaper, where she builds and scales the operational infrastructure that supports Shaper and our companies. 

Prior to Shaper, Elyse held executive roles at category-defining technology companies. As Chief Trust and Safety Officer and Chief Legal Officer at the marketplace Teachers Pay Teachers (TPT), she oversaw operations as the platform scaled to $400 million in sales and led its acquisition by IXL Learning in 2023. Before that, Elyse was VP of Legal at Zocdoc during a period of rapid growth and a $2 billion valuation, and Head of Business Development and General Counsel at MealPal, where she guided the company through global expansion and its Series B funding. 

Elyse began her legal career at Davis Polk & Wardwell and as a clerk for the Honorable Rosemary S. Pooler on the Second Circuit Court of Appeals. She holds a J.D. from Yale Law School and a B.A. from Columbia University with degrees in Economics and Philosophy.

Dr. Engy Ziedan is a Principal Scientist at Protege and an Assistant Professor at Tulane University. As an applied economist, her research includes employing causal inference methods to empirically analyze large-scale, real-world healthcare data. Her findings have been featured in The New York Times and NPR. She earned her PhD in Economics from the University of Illinois Chicago.

Erik Duhaime is the CEO and co-founder of Centaur, a leading provider of data annotation solutions for AI developers in the medical and life sciences. Centaur's novel approach leverages gamification to engage a global network of subject matter experts, providing the highest quality annotations at scale.

Othman Laraki is the CEO of Color Health. Prior to Color, Othman was an early product leader at Google and Twitter and has been a long-time investor and advisor to companies such as AngelList, Slack, Instacart, Gitlab, Coinbase and Pinterest.

Abigail Bertelson is the founder & CEO of Zenith Health, building the evidence base to empower better maternal health. She formerly led patient-mediated clinical data retrieval at Datavant, and is deeply committed to elevating the role of patient-driven data in healthcare innovation.

The Honorable Dr. David J. Shulkin was the ninth Secretary of the US Department of Veterans Affairs in the Trump Administration and VA’s Under Secretary of Health in the Obama Administration. As such, Secretary Shulkin was the only member of the Cabinet to have served both Presidents and to have been confirmed by the US Senate by a vote of 100-0.

Secretary Shulkin served as chief executive of leading hospitals and health systems including Beth Israel in New York City, Morristown Medical Center in Northern NJ and he currently serves on the Board at Sanford Health, one of the country’s largest rural healthcare systems.

Secretary Shulkin is a board-certified internist. He received his medical degree from the Medical College of Pennsylvania, his internship at Yale University School of Medicine, and a residency and Fellowship in General Medicine at the University of Pittsburgh Presbyterian Medical Center. He received advanced training in outcomes research and economics as a Robert Wood Johnson Foundation Clinical Scholar at the University of Pennsylvania. He is on faculty at the Uniformed Health Services Medical School. Over his career Secretary Shulkin has been named “One Hundred Most Influential People in American Healthcare” by Modern Healthcare. He continues to advocate on behalf of the country’s veterans by serving on the board of numerous nonprofits that serve veterans, is the host of the popular Policy Vets Podcast, and is the author of the recent book, “It Shouldn’t Be This Hard to Serve Your Country: Our Broken Government and the Plight of Veterans”.

‍

Stephen M. Hahn, M.D. is the Chief Executive Officer of Harbinger Health and brings two decades of distinguished leadership in healthcare strategy, oncology medical practice, and translational/clinical research to this role. He served as the 24th Commissioner of Food and Drugs at the U.S. Food and Drug Administration (FDA) from 2019 to 2021 overseeing both COVID and non-COVID regulatory affairs, including therapeutics and vaccine development, devices, diagnostics, and clinical trials. Prior to his FDA appointment, Steve served as chief medical executive at the world-renowned MD Anderson Cancer Center in Houston. Prior to his role as chief medical executive, he served as deputy president and chief operating officer where he was responsible for the day-to-day operations of the nation’s top cancer center, which included leading more than 21,000 employees and overseeing a $5.2 billion operating budget. Steve was elevated to the chief operating officer role after serving as division head, department chair, and professor of Radiation Oncology. Prior to his executive leadership roles at MD Anderson, Dr. Hahn was the Chair of Radiation Oncology at the University of Pennsylvania’s Perelman School of Medicine.

Steve focused his translational research efforts on the evaluation of the tumor microenvironment, signal transduction pathways involved in tumor response to therapies and proton therapy. He has authored more than 220 peer-reviewed original research articles and has experience in medical product development. Steve earned his M.D. from Temple University and received his B.A. in Biology from Rice University. He was an internal medicine resident at the University of California San Francisco before completing a fellowship and residency at the National Cancer Institute in Bethesda, Maryland.

‍

Abhinav Shashank is the CEO and co-founder of Innovaccer, a San Francisco-based healthcare AI company on a mission to revolutionize healthcare through innovative technology solutions. Committed to bringing joy back to the practice of medicine and patient care, Abhinav has established himself as an influential strategist with a track record of driving transformative change in the healthcare industry. Under his leadership, Innovaccer has garnered recognition as a national leader in population health management, with over 40 awards and 100+ analyst recognitions. Abhinav's initiatives have resulted in $1.5 billion in cumulative cost savings and partnerships with over 140+ healthcare organizations. His strategic innovations led to a $3.2 billion valuation. Abhinav's influence extends to thought leadership, with over 300 published articles and recognition in “Modern Healthcare’s 40 under 40,” “Becker’s Hospital Review's Rising Stars Healthcare Leaders under 40”, “Goldman Sachs Most Exceptional Entrepreneurs of the Year”, “Fortune India 40 under 40”, and Forbes' "30 Under 30 Asia: Enterprise Tech”. He envisions a future where healthcare becomes 100% consumer-centric and value-driven, leveraging technology for enhanced engagement and outcomes.

Robert M. Califf, MD, MACC, was the Commissioner of Food and Drugs from February 2016 to January 2017 and from February 2022 to January 2025.  He is currently Instructor in Medicine at Duke University School of Medicine.

Between his 2 stints at FDA, Dr. Califf was the head of medical policy and strategy for Alphabet’s subsidiaries Verily and Google Health. 

Previously, Dr. Califf served as the FDA’s Deputy Commissioner for Medical Products and Tobacco from February 2015 until his appointment as Commissioner in February 2016.  

Prior to joining the FDA, Dr. Califf was a professor of medicine and vice chancellor for clinical and translational research at Duke University. He also served as director of the Duke Translational Medicine Institute and founding director of the Duke Clinical Research Institute. A nationally and internationally recognized expert in cardiovascular medicine, health outcomes research, healthcare quality, and clinical research, Dr. Califf has led many landmark clinical trials and is one of the most frequently cited authors in biomedical science, with more than 1,200 publications in the peer-reviewed literature.

Dr. Califf became a Member of the National Academy of Medicine (formerly known as the Institute of Medicine (IOM)) in 2016, one of the highest honors in the fields of health and medicine. Dr. Califf has served on numerous IOM committees, and he has served as a member of the FDA Cardiorenal Advisory Panel and FDA Science Board's Subcommittee on Science and Technology. Dr. Califf has also served on the Board of Scientific Counselors for the National Library of Medicine, as well as on advisory committees for the National Cancer Institute, the National Heart, Lung, and Blood Institute, the National Institute of Environmental Health Sciences and the Council of the National Institute on Aging.

While at Duke, Dr. Califf led major initiatives aimed at improving methods and infrastructure for clinical research, including the Clinical Trials Transformation Initiative (CTTI), a public-private partnership co-founded by the FDA and Duke. He also served as the principal investigator for Duke's Clinical and Translational Science Award and the NIH Health Care Systems Research Collaboratory coordinating center.

Dr. Califf is a graduate of Duke University School of Medicine. He completed a residency in internal medicine at the University of California, San Francisco and a fellowship in cardiology at Duke.

Sarah London is CEO of Centene Corporation, a Fortune 25 company and leading healthcare payer focused on government-sponsored healthcare programs. Centene primarily serves populations that too often face barriers to healthcare access including those with low incomes, complex medical needs, and older Americans. Under London’s leadership, Centene has deepened its commitment to local, personalized care, enhanced company culture, and focused on its core lines of business: Medicaid, Medicare (including Medicare Prescription Drug Plans), and the Health Insurance Marketplace. Appointed CEO in 2022, at just 41 years of age, London has spent her career at the intersection of health data, technology and healthcare delivery transformation. She previously served as Centene’s Vice Chairman, responsible for strategy, technology, enterprise compliance, and a portfolio of independent companies. Before joining Centene she was an Operating Partner at Optum Ventures, the venture capital arm of UnitedHealth Group. She has also held senior roles at Optum Analytics, including Chief Product Officer, as well as Director of Client Operations at Humedica, a clinical analytics start-up. London’s career has been driven by her early experiences working to improve health care for people of all backgrounds at Accretive Health (now R1 RCM) and Health Leeds. London was recently named to Fortune’s “Most Powerful Women list” and was included in the first-ever CNBC “Changemakers: Women Transforming Business.” Additionally, under her leadership, Centene has been recognized by Fortune as one of the “World’s Most Admired Companies” and one of “America’s Most Innovative Companies” and was selected among the “Best Places to Work for People with Disabilities by Disability:IN. London graduated magna cum laude from Harvard College where she played Division I tennis. She also holds a Master of Business Administration with High Honors from the University of Chicago Booth School of Business. She resides in St. Louis with her husband and two young boys.

‍

Mary Varghese Presti is Corporate Vice President of Health & Life Sciences at Microsoft. A healthcare leader with 20+ years of experience, she specializes in driving growth, innovation, and transformation across clinical, commercial, policy, and tech sectors.

Anthony Philippakis is a physician, genomicist, and data scientist. He is a general partner at GV and an institute scientist at the Broad Institute of MIT and Harvard. As a former cardiologist at Brigham and Women’s Hospital, he invests at the intersection of life sciences and machine learning. Anthony is committed to bringing genome sequencing and data science into the practice of clinical medicine.

Anthony’s experience as a cardiologist informs his approach to company creation and investing. “Through my cardiology training, I came to appreciate the potential for data and software to increase the effectiveness of healthcare delivery and improve patient outcomes,” he explains. “I’m excited to push forward a new generation of technology solutions that I want to see in the hospital someday.” In 2016 Anthony spearheaded GV’s incubation of Verve Therapeutics, working closely with the founding team to apply the power of gene editing to develop a one-time treatment for heart disease.

Anthony studied mathematics as an undergraduate at Yale University, followed by a master’s in mathematics at Cambridge University. He completed an M.D. at Harvard Medical School and a Ph.D. in biophysics at Harvard, working to develop computational methods for understanding transcriptional regulation. In addition, he completed his medical residency and cardiology fellowship at Brigham and Women’s Hospital.

‍

Dr. Shiv Rao is the Founder and CEO of Abridge, a generative AI platform that unburdens clinicians from clerical work such as clinical documentation. It integrates directly within EHR clinician workflows, working across care settings, specialties, and spoken languages. Abridge was recently named to the Fortune AI 50, Forbes AI 50, the Forbes Cloud 100, and to TIME’s Best Inventions of 2024 list.

Dr. Rao was also recently named as one of the 100 most influential people in AI by TIME magazine. He is a practicing cardiologist at UPMC, and previously led the provider-facing investment portfolio for UPMC, where he invested in startups and helped fund a Machine Learning in Health program at Carnegie Mellon University. Dr. Rao completed his medical education and training at the University of Michigan and the University of Pittsburgh School of Medicine, and studied at Carnegie Mellon where he programmed virtual synthesizers, and skateboarded in IMAX movies.

‍

Dr. Justin Norden MD, MBA, MPhil is Co-Founder and CEO of Qualified Health - building the infrastructure for Generative AI in healthcare. Additionally, he is an Adjunct Professor at Stanford Medicine in the Department of Biomedical Informatics Research where he teaches the Generative AI and Medicine course.

Previously, Dr. Norden was Co-Founder and CEO of Trustworthy AI, a company focused on algorithm safety and trust, which was acquired by Waymo (Google Self-Driving). He was a Partner at GSR Ventures leading AI in healthcare investments, worked on the healthcare team at Apple, and helped start the Stanford Center for Digital Health.

Dr. Justin Norden received an MD and MBA from Stanford University, an MPhil in Computational Biology from the University of Cambridge, and a BA in Computer Science from Carleton College.

‍

Sachin H. Jain, MD, MBA is CEO of SCAN Group and SCAN Health Plan, one of the nation’s largest not-for-profit Medicare Advantage plans, which serves more than 300,000 members across California, Nevada, Arizona, Texas and New Mexico. Previously, Dr. Jain was President and CEO of CareMore and Aspire Health, which served 200,000 Medicare and Medicaid patients in 32 states. He also served as Chief Medical Information Ramp; Innovation Officer at Merck & Co., was Senior Advisor to the Administrator of the Centers for Medicare & Medicaid Services (CMS) and was the first Deputy Director for policy and programs at the Center for Medicare and Medicaid Innovation (CMMI).

Dr. Jain graduated from Harvard College and earned his MD from Harvard Medical School and MBA from Harvard Business School. He is Adjunct Professor at the Stanford University School of Medicine and is a member of the boards of America's Health Insurance Plans (AHIP), Omada Health, Advantage Healthcare Services, and The Paul & Daisy Soros Fellowships for New Americans.

‍

Aneesh Chopra is the Chief Strategy Officer of Arcadia, a data sharing and analytics platform for value-based care organizations, following the acquisition of CareJourney, a firm he founded following his public service. He served as the first U.S. CTO (2009-2012) and authored "Innovative State: How New Technologies Can Transform Government” (2014).

He serves on the Boards of IntegraConnect, Virginia Center for Health Innovation, and Chairs the George Mason Innovation Advisory Council. He earned his MPP from Harvard Kennedy School and BA from The Johns Hopkins University.

‍

DJ Patil is an entrepreneur, investor, scientist, and leader in public policy. He has held senior roles in industry, academia, and government and his work has been featured in two Michael Lewis books (The Fifth Risk and Premonition). As a General Partner at GreatPoint Ventures he focuses on building companies in healthcare, enterprise technologies, and national security. Notable early stage investments include Figma, Confluent, Tabular, Ola in India, Monte Carlo, Chronosphere, Sumologic, and RelateIQ.

He is a board member for Devoted Health where he was an executive on the founding team and CTO with the mission to build a health care system that takes care of every member like they were family. Previously he led the product teams at RelateIQ which was acquired by Salesforce, and was founding board member for Crisis Text Line which works to use new technologies to provide on demand mental and crisis support. At LinkedIn he was Chief Scientist, Chief Security Officer and led the data efforts which included recommendation systems like People You May Know, Who Viewed My Profile, and Jobs You May Like; new technologies like Kafka; co-coining the term Data Scientist. He has also held a number of roles at Skype, PayPal, and eBay.

Dr. Patil public policy work includes being appointed by President Obama to be the first U.S. Chief Data Scientist where his efforts led to the establishment of nearly 40 Chief Data Officer roles across the Federal government. Establishing new health care programs including the Precision Medicine Initiative (now the NIH All of Us program) and the Cancer Moonshot, new criminal justice reforms including the Data-Driven Justice and Police Data Initiatives that cover more than 94 million Americans, as well as leading the national data efforts. He also has been active in national security and for his efforts was awarded by Secretary Carter the Department of Defense Medal for Distinguished Public Service which is the highest honor the department bestows on a civilian.

He is a member of the Defense Science Board where he led the Taskforce on GenAI, a member of the Board of Visitors for National Defense University, and the Dean’s Fellow at the University of California, Berkeley.

As a member of the faculty at the University of Maryland, his research focused on nonlinear dynamics and chaos theory and he helped start a major research initiative on numerical weather prediction. As an AAAS Science & Technology Policy Fellow for the Department of Defense, Dr. Patil directed new efforts to leverage social network analysis and the melding of computational and social sciences to anticipate emerging threats to the US. He has also co-chaired a major review of US efforts to prevent bioweapons proliferation in Central Asia and co-founded the Iraqi Virtual Science Library (IVSL). And if you’ve read this far, he barely graduated from high school because of his math grades.

‍

Gaurav Singal, MD, is a physician and computer scientist who most recently served as Chief Data Officer at Foundation Medicine, where he led design and build of the company’s RWD product portfolio, in addition to supporting decentralized trials, clinical decision support, and novel diagnostic R&D. Previously, he built NLP software for frontline physicians and founded a number of startups. He is on the faculty and Board of Advisors at Harvard Medical School where he continues to see patients as an Internist. He currently serves as an advisor and investor to a portfolio of companies spanning diagnostics, therapeutics, data science, venture capital, and private equity.

‍

Fawad Butt is the CEO of Penguin AI, a pioneering health AI company headquartered in Palo Alto, California. Penguin AI is revolutionizing U.S. healthcare by tackling its staggering $1 trillion annual administrative expenditure. With a mission to reduce inefficiencies and improve care delivery, Penguin AI delivers cutting-edge AI solutions to payers, providers and RCM companies tailored to healthcare's unique complexities.

Fawad’s journey is marked by a distinguished career in data and analytics leadership. As the Chief Data Officer at industry giants Kaiser Permanente, UnitedHealthcare, and Optum, he led the largest healthcare data and analytics teams, overseeing multi-hundred-million-dollar P&Ls. His transformative initiatives modernized data platforms, integrated advanced technologies, and drove innovations that supported best-in-class care for over 60 million members. Earlier in his career, he shaped global data strategies as the Global Head of Data Strategy at Northern Trust Bank.

A recognized advisor in the healthcare, AI, and technology sectors, Fawad has been instrumental in the success of startups such as Collibra, Monte Carlo Data, and Redesign Health. As an angel investor, he actively supports transformative ventures in AI, Web3, and healthcare technology. His thought leadership is showcased in major publications like Forbes and Fierce Healthcare, and he frequently delivers keynote speeches at industry-leading events.

Fawad holds an MBA from the Kellogg School of Management at Northwestern University and a bachelor’s degree in Electronics Engineering. His work continues to shape the future of healthcare, empowering organizations to harness AI for unparalleled efficiency, equity, and patient outcomes.

‍

Andrew C. von Eschenbach, M.D. currently serves as President of Samaritan Health Initiatives.  In September of 2005, he assumed leadership of the Food and Drug Administration where he immediately engaged an agenda to modernize the FDA. Confirmed by the Senate as Commissioner in December 2006, he emphasized innovation by fostering creative projects, including FDA’s Critical Path Initiative and the FDA’s Food Protection Plan; and an Agency-wide fellowship program and development of a new integrated campus for the Agency in White Oak, Maryland. In addition to expanding FDA’s international role by establishing FDA offices around the world, he internally fostered, through process improvements, a regulatory pathway that is transparent and efficient while still rigorous and science led.  

Dr. von Eschenbach joined FDA after serving for four years as Director of the National Cancer Institute (NCI) at the National Institutes of Health.  At the time of his appointment by President Bush to serve as Director of NCI, he was President-Elect of the American Cancer Society.  Dr. von Eschenbach entered government service after an outstanding career over three decades as a physician, surgeon, oncologist and executive that included numerous leadership roles from Chairman of the Department of Urologic Oncology to Executive Vice President and Chief Academic at the University of Texas M.D. Anderson Cancer Center in Houston.  He is the author of more than 300 scientific articles.  He has received numerous professional awards and honors.  In 2006, Dr. von Eschenbach was named one of Time magazine’s “100 most influential people to shape the world,” and in both 2007 and 2008, he was selected as one of the Modern Healthcare/Modern Physician’s “50 Most Powerful Physician Executives in Healthcare.” 

Dr. von Eschenbach earned a B.S. from St. Joseph’s University in his native Philadelphia and his medical degree from Georgetown University School of Medicine in Washington, D.C.   He served as a Lt. Commander in the U.S. Navy Medical Corps.  After completing a residency in urologic surgery at Pennsylvania Hospital in Philadelphia, he was an instructor in urology at the University of Pennsylvania School of Medicine.  He completed a Fellowship in Urologic Oncology at the University of Texas M.D. Anderson Cancer Center.  

He has been married to his childhood sweetheart, Madelyn, for over 40 years, and they are proud parents of four children and elated grandparents of seven.

‍

Amy is cofounder of Highlander Health, a firm advancing evidence generation and personalized health care for the new era of medical innovation. Amy’s healthcare career is marked by change making in organizations ranging from Flatiron Health to Duke University School of Medicine and Verily. Prior to Verily, Amy served as the principal deputy commissioner of the U.S. Food and Drug Administration from 2019-2021. Her board roles span public companies, such as Athenahealth and CareDx, to private firms, including Insitro and Georgiamune. In addition to her standard setting and innovation work, Amy is a hematologist/oncologist, palliative medicine physician, and author of over 500 publications and counting. 

‍

Dr. Mandy Cohen is the former Director of the CDC and former Secretary of Health and Human Services for North Carolina. Dr. Cohen is one of the nation’s top health leaders with a proven track-record of protecting and improving Americans’ health.

John Wilbanks is head of data at Astera Institute, where he invests in public domain data to accelerate scientific innovation at scale. He has been doing weird things with biological and other kinds of scientific data for over 25 years.

Sergey Stavisky is an Assistant Professor of Neurological Surgery at the University of California, Davis. His lab develops brain-computer interfaces to understand and restore speech and language for people with neurological injuries. He did his PhD and postdoc at Stanford.